Protalix BioTherapeutics (PLX) Shares Outstanding (2010 - 2026)

Protalix BioTherapeutics has reported Shares Outstanding for 17 years, with the latest figure at $80.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 3.12% year-over-year to $80.6 million; the trailing twelve-month figure through Mar 2026 stood at $80.6 million (up 3.12% YoY), and the FY2025 full-year result was $80.4 million, up 6.03% from the prior year.
• Shares Outstanding for Q1 2026 stood at $80.6 million, roughly flat from $80.4 million in the prior quarter.
• The five-year high for Shares Outstanding was $80.6 million in Q1 2026, with the low at $46.3 million in Q1 2022.
• Average Shares Outstanding over 5 years is $69.0 million, with a median of $73.1 million recorded in 2024.
• Year-over-year, Shares Outstanding soared 46.94% in 2023 and rose 0.93% in 2024.
• Tracing PLX's Shares Outstanding over 5 years: stood at $53.8 million in 2022, then soared by 35.62% to $73.0 million in 2023, then rose by 3.97% to $75.9 million in 2024, then advanced by 6.03% to $80.4 million in 2025, then increased by 0.18% to $80.6 million in 2026.
• The last three Shares Outstanding figures came in at $80.6 million (Q1 2026), $80.4 million (Q4 2025), and $80.3 million (Q3 2025), per Business Quant data.

Peer Comparison